Welcome to our dedicated page for Allarity SEC filings (Ticker: ALLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Allarity Therapeutics, Inc. (NASDAQ: ALLR) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Phase 2 clinical-stage biopharmaceutical company focused on stenoparib and its DRP® companion diagnostic platform, Allarity uses SEC reports to communicate material events, financing transactions, and periodic financial information to investors.
Among the key documents available are Form 8-K current reports, where Allarity has disclosed events such as FDA Fast Track designation for stenoparib in advanced ovarian cancer, new clinical data presentations from its Phase 2 ovarian cancer trial, conference participation on biomarkers and precision medicine, licensing and laboratory services agreements for DRP® algorithms, and private placement securities purchase agreements. Filings like NT 10-Q (Form 12b-25) explain timing of quarterly reports and provide context on the status of financial statement reviews.
Through Stock Titan, these filings are supplemented with AI-powered summaries that highlight the main points of each document, helping users quickly understand disclosures related to clinical development, capital structure, registration rights, and governance changes. Real-time updates from EDGAR ensure that new Allarity filings are added as they become available, including quarterly and annual reports when filed, as well as any future Forms 10-K, 10-Q, or additional 8-Ks.
Investors researching ALLR can use this page to review how Allarity describes its business focus on stenoparib and DRP®, track unregistered equity offerings and registration rights agreements, and monitor other material events reported under SEC rules. The combination of original documents and AI-generated overviews is intended to make complex regulatory language more accessible while preserving the underlying source information.
Allarity Therapeutics, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 26, 2026. Proposals include electing one Class I director, ratifying Wolf & Company as auditor for 2026, and an advisory say-on-pay vote on named executive officer compensation.
The company seeks approval to raise its 2021 Equity Incentive Plan share pool from 1,521,990 to 2,021,990 shares and to permit potential issuance of more than 19.99% of outstanding common stock under a $6,000,000 equity line with Tumim Stone Capital, subject to Nasdaq rules and ownership caps. Stockholders are also asked to approve an amendment adding Delaware-permitted officer exculpation and to authorize potential adjournment of the meeting to solicit additional proxies if needed.
Graff Jeremy R. reported acquisition or exercise transactions in this Form 4 filing.
Allarity Therapeutics, Inc. reported that officer Jeremy R. Graff received a grant of 133,333 shares of common stock in the form of restricted stock units on January 28, 2026. The award was granted at a stated price of $0.00 per share as equity compensation.
The RSUs were issued under Allarity Therapeutics, Inc.'s Amended and Restated 2021 Equity Incentive Plan and will vest in three equal installments on the first, second, and third anniversaries of the grant date, as long as Graff maintains a continued relationship with the company. Following this grant, he directly holds 381,644 shares of common stock.
Ervin Jeffrey S reported acquisition or exercise transactions in this Form 4 filing.
Allarity Therapeutics, Inc. reported that its CFO, Jeffrey S. Ervin, received a grant of 150,000 shares of Common Stock in the form of restricted stock units at a stated price of $0.00 per share. Following this award, he holds 150,000 shares directly.
The RSUs were granted on January 28, 2026 under Allarity Therapeutics, Inc.'s Amended and Restated 2021 Equity Incentive Plan. They will vest in equal one-third installments on the first, second, and third anniversaries of the grant date, if he continues his relationship with the company through each vesting date.
Allarity Therapeutics, Inc. reported that the U.S. Patent and Trademark Office has issued a Notice of Allowance for its patent application covering the DRP® companion diagnostic specific to its cancer drug candidate stenoparib. The patent is expected to be formally granted within three months, subject to standard administrative procedures, and would provide exclusivity at least into 2039 for stenoparib when used together with the DRP® test.
The allowed claims cover methods for predicting clinical benefit from stenoparib using gene expression profiles and selecting patients most likely to respond. Allarity already holds European and Australian patents for the Stenoparib DRP® and 18 granted patents for other drug-specific DRPs, including eight in the United States. The company continues Phase 2 development of stenoparib in ovarian cancer and small cell lung cancer while pursuing additional DRP® patent protection globally.
Allarity Therapeutics is registering the resale of up to 255,103 shares of its common stock. This prospectus covers resale of those shares by a selling stockholder (the shares were issued in a private placement on December 23, 2025). The Company will receive no proceeds from these resales.
The prospectus states the selling stockholder may sell the Shares from time to time on Nasdaq or in private transactions at prevailing market or negotiated prices. The prospectus also discloses prior related financings, including a September 23, 2025 private placement generating approximately $2.5 million in gross proceeds and an Additional Closing on December 23, 2025 that issued 255,103 shares at $0.98 per share.
Allarity Therapeutics, Inc. filed Amendment No. 1 to its registration statement (File No. 333-293420) on April 24, 2026 as an exhibits-only amendment to furnish an updated auditor consent. The Amendment updates Exhibit 23.1 and includes the facing page, Item 16, signature page, exhibit index, and filed exhibits; the prospectus is unchanged.
Allarity Therapeutics, Inc. filed a current report describing two new scientific posters on its lead drug candidate stenoparib and its DRP® companion diagnostic, presented at the AACR Annual Meeting 2026 in San Diego.
One poster links higher stenoparib DRP® scores with enhanced overall survival in a phase 2 trial in advanced, recurrent ovarian cancer, supporting DRP-based patient selection. The second poster shows stenoparib’s dual PARP/tankyrase mechanism can modulate the WNT/β-catenin signaling pathway and inhibit growth of colorectal cancer cell lines at clinically relevant concentrations.
The company emphasizes stenoparib’s potential in colorectal and ovarian cancers and highlights ongoing phase 2 trials in ovarian cancer and small cell lung cancer, alongside broader plans to use its DRP® platform to identify patients most likely to benefit from treatment.
Allarity Therapeutics, Inc. has filed a proxy statement for its 2026 Annual Meeting of Stockholders to be held virtually on June 26, 2026. The meeting (record date May 7, 2026) asks shareholders to vote on director election, ratification of Wolf & Company as auditors, an amendment to increase the 2021 Equity Incentive Plan reserve from 1,521,990 to 2,021,990 shares, a non-binding say-on-pay vote, Nasdaq 20% Rule approval related to an equity line providing up to $6,000,000, a certificate amendment to permit officer exculpation (requiring 66-2/3% of outstanding shares to approve), and an adjournment proposal. The proxy explains voting mechanics for virtual attendance, quorum rules (one-third quorum) and broker voting treatments for each proposal.